Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection

Journal of Clinical Microbiology

Volumn 45, Issue 8, 2007, Pages 2439-2445

  Lindh, Magnus ^a,e   Alestig, Erik ^a   Arnholm, Birgitta ^b   Eilard, Anders ^c   Hellstrand, Kristoffer ^a   Lagging, Martin ^a   Wahlberg, Thomas ^d   Wejstål, Rune ^a   Westin, Johan ^a   Norkrans, Gunnar ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Sö dra Alvsborgs sjukhus   (Sweden)

^c UDDEVALLA HOSPITAL   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e Dept of Virology ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CHRONIC HEPATITIS; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RASH; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TREATMENT RESPONSE; VIREMIA;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1;

EID: 34548101708     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00577-07     Document Type: Article

References (27)

1. Bekkering, F. C., C. Stalgis, J. G. McHutchison, J. T. Brouwer, and A. S. Perelson. 2001. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 33:419-423.
2. Berg, T., C. Sarrazin, E. Herrmann, H. Hinrichsen, T. Gerlach, R. Zachoval, B. Wiedenmann, U. Hopf, and S. Zeuzem. 2003. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37:600-609.
3. Berg, T., M. von Wagner, S. Nasser, C. Sarrazin, T. Heintges, T. Gerlach, P. Buggisch, T. Goeser, J. Rasenack, G. R. Pape, W. E. Schmidt, B. Kallinowski, H. Klinker, U. Spengler, P. Martus, U. Alshuth, and S. Zeuzem. 2006. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130:1086-1097.
4. Buti, M., F. Sanchez-Avila, Y. Lurie, C. Stalgis, A. Valdes, M. Martell, and R. Esteban. 2002. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 35:930-936.
5. Carlsson, T., O. Reichard, G. Norkrans, J. Blackberg, P. Sangfelt, E. Wallmark, and O. Weiland. 2005. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J. Viral Hepat. 12:473-480.
6. Davis, G. L., J. B. Wong, J. G. McHutchison, M. P. Manns, J. Harvey, and J. Albrecht. 2003. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38:645-652.
7. Drusano, G. L., and S. L. Preston. 2004. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J. Infect. Dis. 189:964-970.
8. Ferenci, P., M. W. Fried, M. L. Shiffman, C. I. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, M. Chaneac, and K. R. Reddy. 2005. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J. Hepatol. 43:425-433.
9. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
10. Fukutomi, T., M. Nakamuta, M. Fukutomi, M. Iwao, H. Watanabe, K. Hiroshige, Y. Tanabe, and H. Nawata. 2001. Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy. J. Hepatol. 34:100-107.
11. Gavier, B., M. A. Martinez-Gonzalez, J. I. Riezu-Boj, J. J. Lasarte, N. Garcia, M. P. Civeira, and J. Prieto. 1997. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 113:1647-1653.
12. Hadziyannis, S. J., H. Sette, Jr., T. R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer, Jr., D. Bernstein, M. Rizzetto, S. Zeuzem, P. J. Pockros, A. Lin, and A. M. Ackrill. 2004. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346-355.
13. Herrmann, E., J. H. Lee, G. Marinos, M. Modi, and S. Zeuzem. 2003. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37:1351-1358.
14. Jensen, D. M., T. R. Morgan, P. Marcellin, P. J. Pockros, K. R. Reddy, S. J. Hadziyannis, P. Ferenci, A. M. Ackrill, and B. Willems. 2006. Early identi-fication of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kD)/ribavirin therapy. Hepatology 43:954-960.
15. Jessner, W., M. Gschwantler, P. Steindl-Munda, H. Hofer, T. Watkins-Riedel, F. Wrba, C. Mueller, A. Gangl, and P. Ferenci. 2001. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 358:1241-1242.
16. Layden, J. E., and T. J. Layden. 2001. How can mathematics help us understand HCV? Gastroenterology 120:1546-1549.
17. Lindh, M., and C. Hannoun. 2005. Genotyping of hepatitis C virus by Taqman real-time PCR. J. Clin. Virol. 34:108-114.
18. Makiyama, A., Y. Itoh, K. Yasui, K. Mori, M. Okita, M. Nakayama, J. Yamaoka, M. Minami, T. Nakajima, and T. Okanoue. 2006. First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C. Hepatol. Res. 36:94-99.
19. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
20. Martinez-Bauer, E., J. Crespo, M. Romero-Gomez, R. Moreno-Otero, R. Sola, N. Tesei, F. Pons, X. Forns, and J. M. Sanchez-Tapias. 2006. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology 43:72-80.
21. National Institutes of Health. 2002. NIH consensus statement on management of hepatitis C. NIH Consens. State Sci. Statements 19:1-46.
22. Neumann, A. U., N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley, T. J. Layden, and A. S. Perelson. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107.
23. Sanchez-Tapias, J. M., M. Diago, P. Escartin, J. Enriquez, M. Romero-Gomez, R. Barcena, J. Crespo, R. Andrade, E. Martinez-Bauer, R. Perez, M. Testillano, R. Planas, R. Sola, M. Garcia-Bengoechea, J. Garcia-Samaniego, M. Munoz-Sanchez, and R. Moreno-Otero. 2006. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131:451-460.
24. Zeuzem, S., M. Buti, P. Ferenci, J. Sperl, Y. Horsmans, J. Cianciara, E. Ibranyi, O. Weiland, S. Noviello, C. Brass, and J. Albrecht. 2006. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 44:97-103.
25. Zeuzem, S., J. H. Lee, A. Franke, B. Ruster, O. Prummer, G. Herrmann, and W. K. Roth. 1998. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 27:1149-1156.
26. Zeuzem, S., J. M. Pawlotsky, E. Lukasiewicz, M. von Wagner, I. Goulis, Y. Lurie, E. Gianfranco, J. M. Vrolijk, J. I. Esteban, C. Hezode, M. Lagging, F. Negro, A. Soulier, E. Verheij-Hart, B. Hansen, R. Tal, C. Ferrari, S. W. Schalm, and A. U. Neumann. 2005. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J. Hepatol. 43:250-257.
27. Zeuzem, S., J. M. Schmidt, J. H. Lee, B. Ruster, and W. K. Roth. 1996. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 23:366-371.